MedTrace Logo

Study of SOM0226 in Familial Amyloid Polyneuropathy

NCT02191826 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-11-30

No results posted yet for this study

Summary

Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis.

Conditions

  • Familial Amyloid Polyneuropathy (FAP)

Interventions

DRUG

SOM0226

Oral

Sponsors & Collaborators

  • Hospital Vall d'Hebron

    collaborator OTHER

  • SOM Innovation Biotech SA

    lead INDUSTRY

Principal Investigators

  • Josep Gámez, MD · Hospital Vall d'Hebron

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02191826 on ClinicalTrials.gov